Medications for Angioedemas Hereditary

10 results

  • Berinert

    (HUMAN C1-ESTERASE INHIBITOR)
    CSL Behring GmbH
    Usage: BERINERT is indicated for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in both adult and pediatric patients. Its safety and efficacy for prophylactic therapy have not been established.

  • Cinryze

    (HUMAN C1-ESTERASE INHIBITOR)
    Takeda Pharmaceuticals America, Inc.
    Usage: CINRYZE is indicated for routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients (6 years and older) with Hereditary Angioedema (HAE).

  • Firazyr

    (icatibant acetate)
    Takeda Pharmaceuticals America, Inc.
    Usage: FIRAZYR® (icatibant) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older.

  • Haegarda

    (HUMAN C1-ESTERASE INHIBITOR)
    CSL Behring GmbH
    Usage: HAEGARDA is indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients aged 6 years and older.

  • Icatibant (icatibant)

    (Icatibant)
    Alembic Pharmaceuticals Inc.
    Usage: Icatibant injection is indicated for treating acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older.

  • Kalbitor

    (Ecallantide)
    Takeda Pharmaceuticals America, Inc.
    Usage: KALBITOR (ecallantide) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients aged 12 and older.

  • Orladeyo

    (Berotralstat hydrochloride)
    BioCryst Pharmaceuticals Inc.
    Usage: ORLADEYO® is indicated for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 and older. It is not approved for treating acute HAE attacks. Recommended dosage is limited to 150 mg once daily to avoid risks such as QT prolongation.

  • Ruconest

    (c1 esterase inhibitor recombinant)
    Tjoapack Netherlands BV
    Usage: RUCONEST is indicated for treating acute attacks of hereditary angioedema (HAE) in adults and adolescents. Its effectiveness is not established for patients experiencing laryngeal attacks.

  • Sajazir

    (ICATIBANT)
    Cycle Pharmaceuticals Ltd-Uk
    Usage: SAJAZIR (icatibant) injection is indicated for treating acute attacks of hereditary angioedema (HAE) in adults aged 18 and older.

  • Takhzyro

    (lanadelumab-flyo)
    Takeda Pharmaceuticals America, Inc.
    Usage: TAKHZYRO® is indicated for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 2 years and older.